We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.
Compound | Mechanism of Action | Target Indication | Status | More information |
Daridorexant | Dual orexin receptor antagonist | Insomnia | NDA submitted, MAA in preparation | |
Aprocitentan* | Dual endothelin receptor antagonist | Resistant hypertension management | Phase 3 | Investor webcast |
Clazosentan | Endothelin receptor antagonist | Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) | Japan: Filing in preparation Global: Phase 3 |
Investor webcast |
Lucerastat | Glucosylceramide synthase inhibitor | Fabry disease | Phase 3 | Investor webcast |
Selatogrel | P2Y12 receptor antagonist | Suspected acute myocardial infarction | Phase 3 in preparation | |
Cenerimod | S1P1 receptor modulator | Systemic lupus erythematosus | Phase 2 | |
ACT-774312 | CRTH2 receptor antagonist | Nasal polyposis | Phase 2 | |
ACT-539313 | Selective orexin 1 receptor antagonist | Psychiatric disorders | Phase 2 in preparation | |
Sinbaglustat |
GBA2/GCS inhibitor | Rare lysosomal storage disorders | Phase 1 complete | |
ACT-1004-1239 | CXCR7 antagonist | Immunology / Cancer Immunotherapy | Phase 1 | |
ACT-1014-6470 | - | Immunology | Phase 1 | |
ACT-541478 | - | CNS | Phase 1 |
* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide
Neurocrine Biosciences has a global license to develop and commercialize our ACT-709478, a novel T-type calcium channel blocker, for the treatment of a rare form of pediatric epilepsy. In November 2020, Neurocrine announced it had initiated a Phase 2 study for ACT-709478.